ライフサイエンスコーパス: subcutaneous tumor

1 as lower in the liver tumor than that in the subcutaneous tumor.

2 r tumor was significantly higher than in the subcutaneous tumor.

3 n liver tumor was twofold lower than that in subcutaneous tumor.

4 hifted to smaller size compared with that of subcutaneous tumor.

5 Ab to penetrate and bind to cells within the subcutaneous tumors.

6 in the plasma of mice without tumors or with subcutaneous tumors.

7 ive (PD-L1(-)) and PD-L1-positive (PD-L1(+)) subcutaneous tumors.

8 r coincident with central necrosis, than the subcutaneous tumors.

9 skinfold chamber model was used to study the subcutaneous tumors.

10 may be different from those obtained against subcutaneous tumors.

11 it intravital optical techniques to large or subcutaneous tumors.

12 s following intravenous injection but not of subcutaneous tumors.

13 e quantities of VEGF secreted by microscopic subcutaneous tumors (0.5-1 mm(3)) result in an elevation

14 Methods: Mice bearing subcutaneous tumors (50 mm(3), NIH:OVCAR-3) were injecte

15 Mice bearing subcutaneous tumors (50 mm(3), NIH:OVCAR-3) were injecte

16 y also resulted in improved local control of subcutaneous tumor after surgical resection.

17 Growth and vascularization of subcutaneous tumor allografts was enhanced in 2+tRNAi(Me

18 Subcutaneous tumors (amyloidomas) were induced in BALB/c

19 injected into C57BL/6 mice to establish one subcutaneous tumor and multiple lung lesions.

20 The subcutaneous tumors and lung metastases derived from V12

21 rkitt cells reduced their ability to grow as subcutaneous tumors, and caused visible tumor necrosis i

22 ry and sufficient for mAb-induced therapy of subcutaneous tumors, and represent a new and critical fo

23 stiffness of modified collagen matrices and subcutaneous tumors, and show that LOX-induced collagen

24 however, neither ascitic nor transplantable subcutaneous tumors are predictive of activity for solid

25 ptake of (99m)Tc-HuS/Hu-VEGF (n = 10) within subcutaneous tumor as compared with (99m)Tc-HuS/Hu-P4G7

26 lete eradication of injected and noninjected subcutaneous tumors, as well as melanoma tumors in the b

27 d healing, implanted gel foam fragments, and subcutaneous tumor assays, respectively.

28 , were allocated to each of five groups: (a) subcutaneous tumors, (b) kidney tumors, (c) lung tumors

29 A conjugates were evaluated in murine B16F10 subcutaneous tumor-bearing C57BL/6 mice.

30 ficant tumor uptake and good contrast in the subcutaneous tumor-bearing mice, which agreed well with

31 cific fusion protein accumulated not only in subcutaneous tumors but also in lungs and livers affecte

32 lectively reduced the levels of PKC alpha in subcutaneous tumors but not those of protein kinase C ep

33 onist, CD4(+) and CD8(+) T cells infiltrated subcutaneous tumors, but only CD4(+) T cells infiltrated

34 as observed against 10 day, 1 cm established subcutaneous tumors, but only in combination with a boos

35 Unlike the immunity generated against subcutaneous tumors by GM-CSF, however, the effector res

36 coated microneedles suppressed the growth of subcutaneous tumors by ~57%, while a topical cream conta

37 inocytic index' of a particular cell line or subcutaneous tumor can be ascertained within 1-2 d.

38 The recombinant virus still propagated in subcutaneous tumors, causing total regression and sustai

39 te 13-acetate (PMA), inhibited the growth of subcutaneous tumors derived from PAM212 (mouse SCC) and

40 A visible subcutaneous tumor developed in 10-14 days.

41 subgroup of patients who received TILs from subcutaneous tumors, eight of 15 patients receiving unse

42 D scid gamma-(NSG) mice were inoculated with subcutaneous tumors engineered to either be constitutive

43 Mice harboring subcutaneous tumors exhibited elevated levels of DNA dam

44 Subcutaneous tumors expressed less activated Smad-1/5 an

45 FHBG) was performed in mice with established subcutaneous tumors, expressing wild-type HSV1-tk and it

46 Akt activation, cell growth in soft agar, or subcutaneous tumor formation in nude mice.

47 migration and invasion in vitro and enhanced subcutaneous tumor formation in vivo, transforming the m

48 Finally, serial subcutaneous tumor formation using late passage transfor

49 In limiting dilution assays, subcutaneous tumor formation was inhibited by ST6Gal-I k

50 In nude mice, subcutaneous tumors from antisense transfectants showed

51 ferred an advantage for lung metastasis from subcutaneous tumors (fs120/164 vs. fs188/WT); fs120 cell

52 Subcutaneous tumors generated in nude mice by implanting

53 tiology characterized by multiple, recurring subcutaneous tumors, gingival hypertrophy, joint contrac

54 ter RF ablation, coagulation diameter in the subcutaneous tumor groups was the same (mean, 9.8 mm +/-

55 ively determine the oxygen distribution in a subcutaneous tumor growing in rats.

56 nd prodrug activation assays in vitro and in subcutaneous tumors grown from the corresponding cell li

57 gand Sonic Hh (SHH) in these cells decreased subcutaneous tumor growth and decreased stromal cell pro

58 B20-4.1.1 inhibited subcutaneous tumor growth and decreased vascular density

59 ice, there was significant inhibition of the subcutaneous tumor growth and lung metastasis of A549 ce

60 umorsphere-derived cells delayed established subcutaneous tumor growth and strongly impaired pulmonar

61 uggesting that host-expressed Cav-2 promotes subcutaneous tumor growth and tumor-induced neovasculari

62 o assess tumor cell-induced angiogenesis and subcutaneous tumor growth in nude mice using mouse Lewis

63 Subcutaneous tumor growth in nude mice who received intr

64 tered cell cycle progression, and suppressed subcutaneous tumor growth in nude mice.

65 ast, A6 or cisplatin (CDDP) alone suppressed subcutaneous tumor growth in vivo by 48% and 53%, respec

66 ell proliferation and migration in vitro and subcutaneous tumor growth in vivo.

67 cogenic and transforms melanocytes, enabling subcutaneous tumor growth in vivo.

68 Previously it has been shown that subcutaneous tumor growth is enhanced in mice lacking se

69 lation of normal liver can stimulate distant subcutaneous tumor growth mediated by HGF/c-Met pathway

70 s the expression of AGS1/RASD1 inhibited the subcutaneous tumor growth of A549 cells in athymic nude

71 oxic doses in mice resulted in inhibition of subcutaneous tumor growth of cells derived from various

72 lly, exogenous expression of JMJD2B enhanced subcutaneous tumor growth of colon cancer cells in a p53

73 contribution of stromal SPARC, we evaluated subcutaneous tumor growth of TRAMP cell lines in syngene

74 Subcutaneous tumor growth was also prevented from cells

75 pharmacologic or genetic, leads to enhanced subcutaneous tumor growth, similar to the phenotype obse

76 (+/-) mice had increased bone metastatic and subcutaneous tumor growth, suggesting that increased Hh

77 utively active RalB(G23V) exhibited enhanced subcutaneous tumor growth, whereas those transfected wit

78 cle-treated animals, but it had no effect on subcutaneous tumor growth.

79 lation of S100A8 and S100A9 had no effect on subcutaneous tumor growth.

80 decreased bone metastasis without affecting subcutaneous tumor growth.

81 o inhibit in vitro angiogenesis and suppress subcutaneous tumor growth.

82 integrin in hemostasis, bone resorption, and subcutaneous tumor growth.

83 tastatic colonies in lungs without affecting subcutaneous tumor growth.

84 inhibited bone metastasis but did not affect subcutaneous tumor growth.

85 be less efficient in cranial tumors than in subcutaneous tumors, (ii) delivery may be reduced during

86 eplication (U373MG) was adapted to grow as a subcutaneous tumor in nude mice.

87 h knockdown lasting approximately 10 days in subcutaneous tumors in A/J mice and 3-4 weeks in the non

88 erated Moloney murine sarcoma virus, induced subcutaneous tumors in about 14% of infected mice but di

89 R7Delta447, induced brain lesions as well as subcutaneous tumors in all injected mice.

90 ell lines give rise to progressively growing subcutaneous tumors in athymic mice.

91 rm colonies in soft agar and highly invasive subcutaneous tumors in both immunodeficient and immunoco

92 atically reduced, as was the ability to form subcutaneous tumors in CD1 nu/nu mice.

93 s expressing core3 O-glycans barely produced subcutaneous tumors in contrast to robust tumor formatio

94 (-/-) cultures retained the capacity to form subcutaneous tumors in immunocompromised mice.

95 l in vitro but formed fewer and much smaller subcutaneous tumors in mice compared with tumors formed

96 Imaging of subcutaneous tumors in mice was performed by using an ex

97 ngle cell level and in connecting tissues of subcutaneous tumors in mice.

98 act and damaged targeting agents for imaging subcutaneous tumors in mice.

99 lted in a complete regression of established subcutaneous tumors in most animals.

100 mor cells (experimental metastasis) and from subcutaneous tumors in nude mice (spontaneous metastasis

101 Furthermore, treatment of subcutaneous tumors in nude mice with 2-5A-anti-hTR sign

102 and the sphere-forming CSC-like cells formed subcutaneous tumors in nude mice.

103 FGFR-1 cDNAs into human melanomas, grown as subcutaneous tumors in nude mice.

104 Bilateral subcutaneous tumors in rats were treated with either int

105 mulated NK proliferation in vitro and formed subcutaneous tumors in severe combined immunodeficiency/

106 s in nude mice bearing VLA-4-positive B16F10 subcutaneous tumors in the flank were conducted to valid

107 proved the efficacy of paclitaxel to regress subcutaneous tumors in vivo.

108 inistering anti-asialo GM1 antibodies before subcutaneous tumor injection.

109 Using a mouse model with two subcutaneous tumors, it was demonstrated that MRgHIFU en

110 demonstrate that this model is applicable to subcutaneous tumors, lung metastases, and intracranial t

111 A sixth group comprised larger subcutaneous tumors (mean diameter, 46 mm +/- 4) that we

112 ctive T cells into mice bearing a variety of subcutaneous tumors mediated limited antitumor effects a

113 In addition, on generation of a primary subcutaneous tumor, metastasis to regional lymph nodes w

114 am (%ID/g) at 30 min after injection for the subcutaneous tumor model and greater than 1.5 %ID/g for

115 ted regimen of alpha-radioimmunotherapy in a subcutaneous tumor model in mice.

116 as observed at 3-4 d after injection for the subcutaneous tumor model, in contrast to approximately 7

117 In the subcutaneous tumor model, the combined therapy resulted

118 In a subcutaneous tumor model, the combined treatment resulte

119 in the metastasis model and no effect in the subcutaneous tumor model.

120 ficantly increased therapeutic effect in the subcutaneous tumor model.

121 In established pulmonary and subcutaneous tumor models, anti-CD137 synergistically en

122 In vivo, the development of subcutaneous tumor nodules with reduced 6-O-sulfation is

123 by the inaccuracy of caliper measurement of subcutaneous tumors, of counting lung nodules in metasta

124 he tail vein or directly administered to the subcutaneous tumor on 3 or 4 alternating days.

125 nificantly reduced the growth of established subcutaneous tumors relative to either treatment alone.

126 In vivo, injection of AdMIP-3alpha into subcutaneous tumors resulted in local expression of the

127 A-7 in p53-wild-type A549 and p53-null H1299 subcutaneous tumors resulted in significant tumor growth

128 ified DCs (CD40L-DCs) to established (day 8) subcutaneous tumors resulted in sustained tumor regressi

129 as multiple palpable soft pliable nontender subcutaneous tumors scattered over the chest, abdomen, a

130 rmacokinetic and pharmacodynamic analysis in subcutaneous tumors showed that a single administration

131 l adhesion to extracellular matrix proteins, subcutaneous tumor size in nude mice, and invasive behav

132 In mice, overexpression of HAS2 increased subcutaneous tumor size.

133 -to-background contrast, clearly delineating subcutaneous tumor stem cell-derived xenografts from sur

134 he induction of partial regressions of large subcutaneous tumors that exceeded more than 5% of the bo

135 on of the microbiota impairs the response of subcutaneous tumors to CpG-oligonucleotide immunotherapy

136 ress high levels of PTN and metastasize from subcutaneous tumors to the lungs of experimental animals

137 lial lesions precede the onset of peripheral subcutaneous tumors, tumorigenesis progresses through ea

138 Recruitment of monocytes into orthotopic and subcutaneous tumors was significantly increased in these

139 ense and scrambled S-oligodeoxynucleotide in subcutaneous tumors were 2 microM after 21 daily doses o

140 Subcutaneous tumors were established in groups of hamste

141 g in vivo models in which intraperitoneal or subcutaneous tumors were induced in immunodeficient mice

142 These subcutaneous tumors were metastatic to regional lymph no

143 Mice bearing U87-MG and MDA-MB-231 subcutaneous tumors were treated with axitinib (25 mg/kg

144 elomere reserve, cells derived from the ALT+ subcutaneous tumors were unable to generate lung metasta

145 ony-stimulating factor (mM-CSF) never formed subcutaneous tumors when implanted into Fischer rats, wh

146 c cells in SCID mice can engraft and grow as subcutaneous tumors with subsequent dissemination to dis

147 11 of 16 patients with B-lineage ALL grew as subcutaneous tumors, with a significant number subsequen

148 ded the growth of both U87-MG and MDA-MB-231 subcutaneous tumors, with significant differences in tum

149 ced durable and complete remissions of large subcutaneous tumors without detectable side effects.

150 248 was investigated in 2 FLT3-ITD models: a subcutaneous tumor xenograft model and a bone marrow eng

151 f tumor growth in a c-Met amplified (GTL-16) subcutaneous tumor xenograft model and may have an advan

152 ramatically regresses FLT3-ITD tumors in the subcutaneous tumor xenograft model and prolongs survival

153 ion had no effect on cell growth in vitro or subcutaneous tumor xenograft-growth in vivo.

154 tic effects against cultured tumor cells and subcutaneous tumor xenografts established in athymic mic

155 ke were examined in CD1 athymic mice bearing subcutaneous tumor xenografts that expressed HER2, HER3,

156 partially delayed progression of established subcutaneous tumor xenografts, whereas combined treatmen

157 IN or human pancreatic cancer cells grown as subcutaneous tumor xenografts.

158 , n = 12; control group, n = 14) with U87 MG subcutaneous tumor xenografts.